Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Loidi JC, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios Jefe J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Salinas NE, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Rosso RG, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Robles EM, Matteelli A, Mazza-Stalder J, Moschos C, Munoz-Torrico M, Hamdan HM, Nakčerienė B, Nicod L, Marcos MN, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Oct 10. pii: 1901522. doi: 10.1183/13993003.01522-2019. [Epub ahead of print]

PMID:
31601711
3.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

4.

Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014.

Karo B, Kohlenberg A, Hollo V, Duarte R, Fiebig L, Jackson S, Kearns C, Ködmön C, Korzeniewska-Kosela M, Papaventsis D, Solovic I, van Soolingen D, van der Werf MJ.

Euro Surveill. 2019 Mar;24(12). doi: 10.2807/1560-7917.ES.2019.24.12.1800392.

5.

Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study.

Sane Schepisi M, Navarra A, Altet Gomez MN, Dudnyk A, Dyrhol-Riise AM, Esteban J, Giorgetti PF, Gualano G, Guglielmetti L, Heyckendorf J, Kaluzhenina A, Lange B, Lange C, Manika K, Miah J, Nanovic Z, Pontali E, Prego MR, Solovic I, Tiberi S, Palmieri F, Girardi E.

Open Forum Infect Dis. 2018 Dec 19;6(1):ofy337. doi: 10.1093/ofid/ofy337. eCollection 2019 Jan.

6.

Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area.

Rosales-Klintz S, Bruchfeld J, Haas W, Heldal E, Houben RMGJ, van Kessel F, Mandelbaum M, Matteelli A, Migliori GB, Oordt-Speets A, Solovic I, Vašáková M, Verver S, de Vlas SJ, Vonk Noordegraaf-Schouten MJM, de Vries G, Zenner D, van der Werf MJ.

Eur Respir J. 2019 Jan 17;53(1). pii: 1802077. doi: 10.1183/13993003.02077-2018. Print 2019 Jan. No abstract available.

PMID:
30655449
7.

Dibasic Derivatives of Phenylcarbamic Acid against Mycobacterial Strains: Old Drugs and New Tricks?

Malík I, Csöllei J, Solovič I, Pospíšilová Š, Michnová H, Jampílek J, Čížek A, Kapustíková I, Čurillová J, Pecháčová M, Stolaříková J, Pecher D, Oravec M.

Molecules. 2018 Sep 28;23(10). pii: E2493. doi: 10.3390/molecules23102493.

8.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
9.

Migration, TB control and elimination: Whom to screen and treat.

Rendon A, Centis R, Zellweger JP, Solovic I, Torres-Duque CA, Robalo Cordeiro C, de Queiroz Mello FC, Manissero D, Sotgiu G.

Pulmonology. 2018 Mar - Apr;24(2):99-105. doi: 10.1016/j.rppnen.2017.11.007. Epub 2017 Dec 29. Review.

10.

Synthesis and In Vitro Antimycobacterial Activity of Novel N-Arylpiperazines Containing an Ethane-1,2-diyl Connecting Chain.

Goněc T, Malík I, Csöllei J, Jampílek J, Stolaříková J, Solovič I, Mikuš P, Keltošová S, Kollár P, O'Mahony J, Coffey A.

Molecules. 2017 Nov 30;22(12). pii: E2100. doi: 10.3390/molecules22122100.

11.

Tuberculosis as Public Health Problem in the Slovak Republic.

Samohyl M, Solovic I, Svecova J, Rams R, Hirosova K, Jurkovicova J.

Iran J Public Health. 2017 Jun;46(6):852-853. No abstract available.

12.

Standard operating procedures for tuberculosis care.

Solovic I, Abubakar I, Sotgiu G, Dara M, Goletti D, Duarte R, Aliberti S, de Benedictis FM, Ward B, Teixeira V, Gratziou C, Migliori GB.

Eur Respir J. 2017 Jun 1;49(6). pii: 1700515. doi: 10.1183/13993003.00515-2017. Print 2017 Jun. No abstract available.

13.

World TB Day 2017: Strengthening the fight against TB.

Solovic I, Centis R, D'Ambrosio L, Visca D, Battista Migliori G.

Presse Med. 2017 Mar;46(2 Pt 2):e1-e4. doi: 10.1016/j.lpm.2017.02.002. No abstract available.

PMID:
28336002
14.

Breaking the barriers: Migrants and tuberculosis.

Sotgiu G, Dara M, Centis R, Matteelli A, Solovic I, Gratziou C, Rendon A, Battista Migliori G.

Presse Med. 2017 Mar;46(2 Pt 2):e5-e11. doi: 10.1016/j.lpm.2017.01.013. Epub 2017 Feb 28. Review.

PMID:
28256381
15.

European policies in the management of tuberculosis among migrants.

D'Ambrosio L, Centis R, Dara M, Solovic I, Sulis G, Zumla A, Migliori GB.

Int J Infect Dis. 2017 Mar;56:85-89. doi: 10.1016/j.ijid.2016.11.002. Epub 2016 Nov 9.

16.

Non-Tuberculous Mycobacteria: Classification, Diagnostics, and Therapy.

Porvaznik I, Solovič I, Mokrý J.

Adv Exp Med Biol. 2017;944:19-25. Review.

PMID:
27826888
17.

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.

Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Alffenaar JW, Caminero JA, Abdo Arbex M, Alarcon Guizado V, Aleksa A, Dore S, Gaga M, Gualano G, Kunst H, Payen MC, Roby Arias AJ, Skrahina A, Solovic I, Sulis G, Tadolini M, Zumla A, Migliori GB; International Carbapenem Study Group.

Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1. No abstract available.

18.

Pregnancy in patients with tuberculosis: a TBNET cross-sectional survey.

Bothamley GH, Ehlers C, Salonka I, Skrahina A, Orcau A, Codecasa LR, Ferrarese M, Pesut D, Solovic I, Dudnyk A, Anibarro L, Denkinger C, Guglielmetti L, Muylle I, Confalonieri M.

BMC Pregnancy Childbirth. 2016 Oct 12;16(1):304.

19.

Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices.

Dara M, Solovic I, Sotgiu G, D'Ambrosio L, Centis R, Tran R, Goletti D, Duarte R, Aliberti S, de Benedictis FM, Bothamley G, Schaberg T, Abubakar I, Teixeira V, Ward B, Gratziou C, Migliori GB.

Eur Respir J. 2016 Sep;48(3):808-17. doi: 10.1183/13993003.00840-2016. Epub 2016 Aug 4.

20.

Preventing and controlling tuberculosis among refugees in Europe: more is needed.

Dara M, Solovic I, Goletti D, Sotgiu G, Centis R, D'Ambrosio L, Ward B, Teixeira V, Gratziou C, Migliori GB.

Eur Respir J. 2016 Jul;48(1):272-4. doi: 10.1183/13993003.00329-2016. No abstract available.

21.

Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Jun;47(6):1758-66. doi: 10.1183/13993003.00214-2016. Epub 2016 Apr 13.

22.

Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees: Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease.

Dara M, Solovic I, Sotgiu G, D'Ambrosio L, Centis R, Goletti D, Duarte R, Aliberti S, de Benedictis FM, Bothamley G, Schaberg T, Abubakar I, Ward B, Teixeira V, Gratziou C, Migliori GB.

Eur Respir J. 2016 May;47(5):1345-7. doi: 10.1183/13993003.00377-2016. Epub 2016 Mar 23. No abstract available.

23.

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10.

24.

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16. No abstract available.

PMID:
26908794
25.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

26.

Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays. A Tuberculosis Network European Trials Group Study.

Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunschi R, Bogyi M, Bothamley G, Bothe C, Codecasa L, Costa P, Dominguez J, Duarte R, Fløe A, Fresard I, García-García JM, Goletti D, Halm P, Hellwig D, Henninger E, Heykes-Uden H, Horn L, Kruczak K, Latorre I, Pache G, Rath H, Ringshausen FC, Ruiz AS, Solovic I, Souza-Galvão ML, Widmer U, Witte P, Lange C; TBNET.

Am J Respir Crit Care Med. 2015 May 15;191(10):1176-84. doi: 10.1164/rccm.201502-0232OC.

PMID:
25763458
27.

Illness perception in tuberculosis by implementation of the Brief Illness Perception Questionnaire - a TBNET study.

Pesut DP, Bursuc BN, Bulajic MV, Solovic I, Kruczak K, Duarte R, Sorete-Arbore A, Raileanu M, Strambu I, Nagorni-Obradovic L, Adzic T, Lazic Z, Zlatev-Ionescu M, Bhagyabati S, Singh II, Srivastava GN.

Springerplus. 2014 Nov 8;3:664. doi: 10.1186/2193-1801-3-664. eCollection 2014.

28.

Classical against molecular-genetic methods for susceptibility testing of antituberculotics.

Porvaznik I, Mokry J, Solovic I.

Adv Exp Med Biol. 2015;835:15-22. doi: 10.1007/5584_2014_28.

PMID:
25252893
29.

Regional advisory board position statement on optimal pneumococcal vaccination in adults. Update to 2011 consensus on adult pneumococcal disease: update on optimal pneumococcal vaccination in adults.

Ludwig E, Unal S, Bogdan M, Chlíbek R, Ivanov Y, Kozlov R, Lode H, Mészner Z, Prymula R, Rahav G, Skoczyńska A, Solovic I, Sayiner A.

Cent Eur J Public Health. 2013 Dec;21(4):233-6.

30.

Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia.

Tichopad A, Roberts C, Gembula I, Hajek P, Skoczynska A, Hryniewicz W, Jahnz-Rozyk K, Prymula R, Solovič I, Kolek V.

PLoS One. 2013 Aug 6;8(8):e71375. doi: 10.1371/journal.pone.0071375. Print 2013.

31.

Challenges in diagnosing extrapulmonary tuberculosis in the European Union, 2011.

Solovic I, Jonsson J, Korzeniewska-Koseła M, Chiotan DI, Pace-Asciak A, Slump E, Rumetshofer R, Abubakar I, Kos S, Svetina-Sorli P, Haas W, Bauer T, Sandgren A, van der Werf MJ.

Euro Surveill. 2013 Mar 21;18(12). pii: 20432.

32.

Opportunity for healthy ageing: lessening the burden of adult pneumococcal disease in Central and Eastern Europe, and Israel.

Ludwig E, Unal S, Bogdan M, Chlibek R, Ivanov Y, Kozlov R, van der Linden M, Lode H, Mészner Z, Prymula R, Rahav G, Skoczynska A, Solovic I, Uzaslan E.

Cent Eur J Public Health. 2012 Jun;20(2):121-5.

33.

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement.

Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C.

Eur Respir J. 2010 Nov;36(5):1185-206. doi: 10.1183/09031936.00028510. Epub 2010 Jun 7.

34.

LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement.

Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Hölscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM; C. Lange; TBNET.

Eur Respir J. 2009 May;33(5):956-73. doi: 10.1183/09031936.00120908.

35.

The effectiveness for prevention of tuberculosis in patients with inflammatory rheumatic diseases treated with TNF inhibitors.

Rybar I, Rozborilova E, Zanova E, Micekova D, Solovic I, Rovensky J.

Bratisl Lek Listy. 2008;109(4):164-7.

PMID:
18814432

Supplemental Content

Loading ...
Support Center